Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 24, 2016New England Journal of MedicineOpen Access

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

APAntonio PalumboSemmelweis UniversityACAsher Chanan‐KhanWinnMedKWKatja WeiselUniversität Hamburg

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Palumbo et al. (2016) studied this question.

synapsesocial.com/papers/6a7cf553448628eb7e2fa746https://doi.org/10.1056/nejmoa1606038
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference2016 · 124 citations
  2. 2Impact of Novel Treatments on Multiple Myeloma Survival2014 · 7 citations
  3. 3Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma2004 · 363 citations
  4. 4The risk of secondary primary malignancies after therapy for multiple myeloma2015 · 16 citations
  5. 5International Staging System for Multiple Myeloma2005 · 2,959 citations